Integrated exome and RNA sequencing of dedifferentiated liposarcoma

去分化脂肪肉瘤的整合外显子组和RNA测序

阅读:2
作者:Makoto Hirata # ,Naofumi Asano # ,Kotoe Katayama # ,Akihiko Yoshida ,Yusuke Tsuda ,Masaya Sekimizu ,Sachiyo Mitani ,Eisuke Kobayashi ,Motokiyo Komiyama ,Hiroyuki Fujimoto ,Takahiro Goto ,Yukihide Iwamoto ,Norifumi Naka ,Shintaro Iwata ,Yoshihiro Nishida ,Toru Hiruma ,Hiroaki Hiraga ,Hirotaka Kawano ,Toru Motoi ,Yoshinao Oda ,Daisuke Matsubara ,Masashi Fujita ,Tatsuhiro Shibata ,Hidewaki Nakagawa ,Robert Nakayama ,Tadashi Kondo ,Seiya Imoto ,Satoru Miyano ,Akira Kawai ,Rui Yamaguchi ,Hitoshi Ichikawa ,Koichi Matsuda

Abstract

The genomic characteristics of dedifferentiated liposarcoma (DDLPS) that are associated with clinical features remain to be identified. Here, we conduct integrated whole exome and RNA sequencing analysis in 115 DDLPS tumors and perform comparative genomic analysis of well-differentiated and dedifferentiated components from eight DDLPS samples. Several somatic copy-number alterations (SCNAs), including the gain of 12q15, are identified as frequent genomic alterations. CTDSP1/2-DNM3OS fusion genes are identified in a subset of DDLPS tumors. Based on the association of SCNAs with clinical features, the DDLPS tumors are clustered into three groups. This clustering can predict the clinical outcome independently. The comparative analysis between well-differentiated and dedifferentiated components identify two categories of genomic alterations: shared alterations, associated with tumorigenesis, and dedifferentiated-specific alterations, associated with malignant transformation. This large-scale genomic analysis reveals the mechanisms underlying the development and progression of DDLPS and provides insights that could contribute to the refinement of DDLPS management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。